Legacy Education Delivers Record Fiscal 2026 Results with 25% Revenue Growth and Continued Enrollment Gains

Legacy Education reported fiscal 2026 revenue of $80.1 million, up 24.8% year over year, while net income increased 21.3% to $9.1 million and diluted EPS rose 11.9% to $0.66. Q4 revenue grew 12.0% to $20.1 million, with net income up 53.3% to $1.9 million and adjusted EBITDA rising to $3.1 million from $2.4 million. Enrollment momentum remained positive, with new student starts up 9.0% and year-end student population up 8.9% to 3,377, alongside campus expansions and a planned first Texas campus in Houston.

Analysis

The key valuation question is whether LGCY can convert capacity additions and the Texas launch into organic enrollment without further sacrificing unit economics. Underlying enrollment growth materially trails reported revenue growth once acquisition-period comparability is removed, while educational-services and G&A ratios have not demonstrated operating leverage. The near-term earnings beat therefore supports sentiment, but not yet a durable multiple re-rating; investors should focus on starts, revenue per student, and marketing cost per start rather than adjusted EBITDA.

Credit-quality risk is the underappreciated constraint. Bad-debt expense remains large relative to revenue and is tied to a growing receivables base; a deterioration in student completion, financing availability, or collections can erase the modest operating-margin cushion quickly. Expansion also front-loads lease, staffing, regulatory, and student-acquisition costs, making the next two to four quarters more likely to show margin dilution before any campus maturation benefit. The company’s cash position limits immediate balance-sheet stress, but does not protect the equity from de novo campus execution risk.

For the next several days, a low-float NYSE American issuer can trade sharply on headline momentum, especially if management provides explicit FY27 enrollment and margin targets on the call. Over one to three months, the catalyst path is proof that new programs and capacity produce starts at stable marketing intensity; absent that disclosure, the release is largely confirmatory. Over six to eighteen months, a successful Texas expansion could broaden the addressable market, but it also exposes LGCY to a more competitive healthcare-training market and state-specific approval/compliance risk.

Contrarian view: the reported profit acceleration may overstate the quality of growth because the quarter benefits from easier acquisition comparisons and a lower tax burden, while diluted share growth is restrained by rising dilution. A favorable risk/reward setup requires evidence that incremental revenue converts at meaningfully better than the current operating margin, not simply continued top-line expansion.

Key Decisions for Investors

• Do not chase a post-release spike in LGCY; place on watch through the earnings call and initiate only if management quantifies FY27 organic starts growth above 12% and holds bad debt at or below 5% of revenue. Target a 3-6 month long only after those KPIs are independently visible in the next quarterly filing.
• For an existing LGCY long, retain a reduced tactical position into the call but use a 10-12% downside stop from entry; exit if FY27 guidance implies further operating-margin compression or if marketing expense grows faster than starts for a second consecutive quarter.
• Use a 1-3 month relative-value screen rather than a broad education-sector pair: compare LGCY’s implied EV/EBITDA and organic enrollment growth against UTI and ATGE after their next results. There is insufficient disclosed valuation, float, and borrow data to recommend a funded pair today.
• Set alerts for accounts receivable growth exceeding revenue growth by more than 10 percentage points, bad debt above 6% of revenue, or any accreditation/approval delay in Texas; any of these would falsify the operating-leverage thesis and favor avoiding or shorting post-rally liquidity.